Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rifabutin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB11 | O95342 | 3/20 | 0.72 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.72 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.72 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.72 |
| ▸ | ABCC2 | Q92887 | 2/20 | 0.72 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.72 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.70 |
| ▸ | MAPT | P10636 | 3/20 | 0.70 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.70 |
| ▸ | TSHR | P16473 | 2/20 | 0.70 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.70 |
| ▸ | LMNA | P02545 | 1/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.70 |
| ▸ | POLB | P06746 | 1/20 | 0.70 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.70 |
| ▸ | SLCO2B1 | O94956 | 2/20 | 0.59 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.59 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.59 |
| ▸ | SLCO1A2 | P46721 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rifabutin SCHEMBL1813946 | 1.00 | ABCB11 (0.72) | ABCB11CHRM1PTGS1ABCC4ABCC2 | |
| Rifabutin SCHEMBL17705915 | 1.00 | ABCB11 (0.72) | ABCB11CHRM1PTGS1ABCC4ABCC2 | |
| Rifabutin SCHEMBL36044 | 1.00 | ABCB11 (0.72) | ABCB11CHRM1PTGS1ABCC4ABCC2 | |
| Rifabutin SCHEMBL28325467 | 1.00 | ABCB11 (0.72) | ABCB11CHRM1PTGS1ABCC4ABCC2 | |
| Rifabutin SCHEMBL41044 | 1.00 | ABCB11 (0.72) | ABCB11CHRM1PTGS1ABCC4ABCC2 | |
| Rifabutin SCHEMBL23106966 | 1.00 | ABCB11 (0.72) | ABCB11CHRM1PTGS1ABCC4ABCC2 | |
| Rifabutin SCHEMBL36043 | 1.00 | ABCB11 (0.72) | ABCB11CHRM1PTGS1ABCC4ABCC2 | |
| Rifabutin SCHEMBL7778399 | 0.98 | ABCB11 (0.70) | ABCB11CHRM1PTGS1ABCC4ABCC2 | |
| Rifabutin SCHEMBL173466 | 0.98 | ABCB11 (0.70) | ABCB11CHRM1PTGS1ABCC4ABCC2 | |
| Rifabutin SCHEMBL155626 | 0.98 | ABCB11 (0.70) | ABCB11CHRM1PTGS1ABCC4ABCC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113583021-B | Synthesis method of spiropiperidine rifamycin | 漯河启福医药科技有限公司 | 2023-05-23 | — | — | CN | disclosed |
| US-11291670-B2 | Therapeutic approaches for treating Alzheimer disease and related disorders through a modulation of angiogenesis | PHARNEXT (FR) | 2022-04-05 | — | — | US | disclosed |
| CN-113583021-A | Synthesis method of spiropiperidine rifamycin | 四川樵枫科技发展有限公司 | 2021-11-02 | — | — | CN | disclosed |
| US-20210144998-A1 | COMPOSITIONS AND METHODS FOR TREATING HUANGLONGBING DISEASE IN CITRUS | NEW LIFE CROP SCIENCES LLC | 2021-05-20 | — | — | US | disclosed |
| EP-3797767-A1 | LEVOSIMENDAN FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS | Pharnext (FR) | 2021-03-31 | — | — | EP | disclosed |
| CN-112430266-A | Anti-muramic acid antibodies and conjugates | 基因泰克公司 | 2021-03-02 | — | — | CN | disclosed |
| EP-3423457-B1 | PROCESS FOR THE PREPARATION OF AN ANTIBODY-RIFAMYCIN CONJUGATE | HOFFMANN LA ROCHE (CH) | 2021-02-17 | — | — | EP | disclosed |
| US-10874644-B2 | Therapeutic approaches for treating Alzheimer disease and related disorders through a modulation of synapse function | PHARNEXT (FR) | 2020-12-29 | — | — | US | disclosed |
| CN-105358573-B | Anti-muramic acid antibodies and conjugates | 基因泰克公司 | 2020-10-30 | — | — | CN | disclosed |
| US-10689325-B2 | Process for the preparation of an antibody-rifamycin conjugate | GENENTECH, INC. (US) | 2020-06-23 | — | — | US | disclosed |
| US-20120270836-A1 | THERAPEUTIC APPROACHES FOR TREATING ALZHEIMER'S DISEASE | PHARNEXT (FR) | 2012-10-25 | — | — | US | disclosed |
| US-20120196887-A1 | METHODS AND COMPOSITIONS FOR IMPROVED RIFAMYCIN THERAPIES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-08-02 | — | — | US | disclosed |
| US-20120071483-A1 | THERAPEUTIC APPROACHES FOR TREATING ALZHEIMER DISEASE AND RELATED DISORDERS THROUGH A MODULATION OF CELL STRESS RESPONSE | PHARNEXT (FR) | 2012-03-22 | — | — | US | disclosed |
| US-20120058992-A1 | THERAPEUTIC APPROACHES FOR TREATING ALZHEIMER DISEASE AND RELATED DISORDERS THROUGH A MODULATION OF ANGIOGENESIS | PHARNEXT (FR) | 2012-03-08 | — | — | US | disclosed |
| US-20110269764-A1 | THERAPEUTIC APPROACHES FOR TREATING ALZHEIMER DISEASE AND RELATED DISORDERS THROUGH A MODULATION OF SYNAPSE FUNCTION | PHARNEXT (FR) | 2011-11-03 | — | — | US | disclosed |
| EP-2322163-A1 | New therapeutics approaches for treating alzheimer disease | Pharnext (FR) | 2011-05-18 | — | — | EP | disclosed |
| CN-102065898-A | Novel therapeutic approaches for treating alzheimer's disease and related disorders by modulating angiogenesis | PHARNEXT | 2011-05-18 | — | — | CN | disclosed |
| CN-102065897-A | New therapeutic approaches for treating alzheimer disease and related disorders through a modulation of cell stress response | PHARNEXT | 2011-05-18 | — | — | CN | disclosed |
| CN-102065858-A | Combination compositions for treating alzheimer's disease and related conditions using zonisamide and acamprosate | PHARNEXT | 2011-05-18 | — | — | CN | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10689325-B2 | Process for the preparation of an antibody-rifamycin conjugate | FUCA2, MRPL21, FNTB | ABCB11 380/4885CHRM1 2257/4885PTGS1 4725/4885 |
| US-20120196887-A1 | METHODS AND COMPOSITIONS FOR IMPROVED RIFAMYCIN THERAPIES | NR1H4, ABCB11, RIF1 | ABCB11 2/4885CHRM1 4858/4885PTGS1 3786/4885 |
| US-20210144998-A1 | COMPOSITIONS AND METHODS FOR TREATING HUANGLONGBING DISEASE IN CITRUS | PNPO, G6PD, AGXT | ABCB11 1266/4885CHRM1 1173/4885PTGS1 1475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.